New Drug Approvals in Acute Myeloid Leukemia: An Unprecedented Paradigm Shift

Abstract: We are witnessing an unprecedented paradigm shift in the treatment of acute myeloid leukemia (AML). For nearly 4 decades—since the introduction of cytarabine- and anthracycline-based […]